Burns G F, Cawley J C
Br J Haematol. 1979 Aug;42(4):499-505. doi: 10.1111/j.1365-2141.1979.tb01162.x.
An immunological surface marker study was performed on 13 patients with a variety of myeloid leukaemias. It was shown that expression of the receptor for the Fc of IgG (gamma FcR) starts to take place at the promyelocyte stage, and that the receptor is present on more mature granulocytic cells, but is absent from myeloblasts. Myeloblasts and promyelocytes are negative for the complement receptor CR2. Monoblasts, unlike myelobasts, were shown to express a gamma FcR and, to a lesser extent, CR2. Receptor expression therefore appears to be an earlier event in monocytic development. The possible diagnostic value of immunological marker studies in myeloid disorders is considered.
对13例患有各种髓系白血病的患者进行了免疫表面标志物研究。结果表明，IgG的Fc受体（γFcR）在早幼粒细胞阶段开始表达，该受体存在于更成熟的粒细胞上，但在原始粒细胞上不存在。原始粒细胞和早幼粒细胞的补体受体CR2呈阴性。与原始粒细胞不同，单核细胞显示表达γFcR，且在较小程度上表达CR2。因此，受体表达似乎是单核细胞发育中更早出现的事件。文中考虑了免疫标志物研究在髓系疾病中的可能诊断价值。
